Markus Aebi
Corporate Officer/Principal at Institute of Microbiology
Markus Aebi active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Institute of Microbiology | Corporate Officer/Principal | 2011-09-21 | - |
Career history of Markus Aebi
Former positions of Markus Aebi
| Companies | Position | Start | End |
|---|---|---|---|
| Swiss National Science Foundation | Corporate Officer/Principal | 1993-12-31 | 1993-12-31 |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Chief Tech/Sci/R&D Officer | 2010-04-30 | - |
| Founder | 2010-04-30 | - |
Training of Markus Aebi
| University of Zurich | Doctorate Degree |
| California Institute of Technology | Undergraduate Degree |
Statistics
International
| Switzerland | 4 |
| Bulgaria | 2 |
| United States | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
| Swiss National Science Foundation |
- Stock Market
- Insiders
- Markus Aebi
- Experience
